KARYOPHARM THERAPEUTICS INC (KPTI)

US48576U1060 - Common Stock

1.58  +0.1 (+6.76%)

News Image
22 days ago - Karyopharm Therapeutics Inc.

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Image
a month ago - Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Image
a month ago - The Motley Fool

Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript

KPTI earnings call for the period ending December 31, 2023.

News Image
a month ago - Karyopharm Therapeutics Inc.

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

– Total Revenue of $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $112 Million for Full Year 2023, Meeting Company's Guidance – – Top-Line...

News Image
a month ago - InvestorPlace

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money.

News Image
a month ago - Karyopharm Therapeutics Inc.

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...

News Image
2 months ago - Market News Video

Notable Tuesday Option Activity: LSEA, KR, KPTI

News Image
2 months ago - Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Image
3 months ago - Seeking Alpha

Karyopharm expects FY total revenue to be ~$145.9 million (NASDAQ:KPTI)

Karyopharm expects strong Q4 and FY revenue, with cash reserves to last into late 2025.

News Image
3 months ago - Karyopharm Therapeutics Inc.

Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives

– Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor...

News Image
3 months ago - Karyopharm Therapeutics Inc.

Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Image
3 months ago - Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Image
4 months ago - Antengene Corporation Limited

Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

News Image
4 months ago - Karyopharm Therapeutics Inc.

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced...

News Image
4 months ago - Antengene Corporation Limited

Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

News Image
4 months ago - Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Image
5 months ago - Karyopharm Therapeutics Inc.

Karyopharm to Participate at Upcoming Investor Conferences

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Image
5 months ago - The Motley Fool

Karyopharm Therapeutics (KPTI) Q3 2023 Earnings Call Transcript

KPTI earnings call for the period ending September 30, 2023.

News Image
5 months ago - Karyopharm Therapeutics Inc.

Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Image
5 months ago - Karyopharm Therapeutics Inc.

Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

– Achieved Third Quarter 2023 Total Revenue of $36.0 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $30.2 Million – – Maintains Full Year 2023...

News Image
5 months ago - Seeking Alpha

Karyopharm, Bristol Myers to evaluate drug combination for multiple myeloma (NASDAQ:KPTI)

Karyopharm Therapeutics is collaborating with Bristol Myers Squibb to evaluate a drug combination for multiple myeloma patients. Read more here.

News Image
5 months ago - Karyopharm Therapeutics Inc.

Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Image
5 months ago - Karyopharm Therapeutics Inc.

Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...

News Image
6 months ago - Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Image
6 months ago - Karyopharm Therapeutics Inc.

Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Image
7 months ago - Karyopharm Therapeutics Inc.

Karyopharm to Participate at Upcoming Investor Conferences

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Image
7 months ago - Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Image
7 months ago - Karyopharm Therapeutics Inc.

Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...

News Image
8 months ago - Antengene Corporation Limited

Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China

- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China, broadening coverage and...

News Image
8 months ago - The Motley Fool

Karyopharm Therapeutics (KPTI) Q2 2023 Earnings Call Transcript

KPTI earnings call for the period ending June 30, 2023.